Furthermore, targeting proteins that interact with DDX21 or regulating these interactions such as using WDR5 inhibitors or blocking the DDX21-WDR5-CDC5L interaction offers additional possibilities for CRC treatment. This evidence concerns the gene DDX21 and colorectal carcinoma.